Filing Details
- Accession Number:
- 0000947871-19-000336
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-06 17:28:18
- Reporting Period:
- 2019-05-02
- Accepted Time:
- 2019-05-06 17:28:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1404281 | Novus Therapeutics Inc. | NVUS | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1706399 | Erez Chimovits | C/O Novus Therapeutics, Inc. 19900 Macarthur Blvd., Suite 550 Irvine CA 92612 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-05-02 | 646,204 | $3.10 | 3,183,314 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrants to Purchase Common Stock | Acquisiton | 2019-05-02 | 646,204 | $0.00 | 646,204 | $0.00 |
| Common Stock | Warrants to Purchase Common Stock | Acquisiton | 2019-05-02 | 646,204 | $0.00 | 646,204 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 646,204 | 2019-05-02 | 2020-11-02 | No | 4 | P | Indirect |
| 646,204 | 2019-05-02 | 2024-05-02 | No | 4 | P | Indirect |
Footnotes
- The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.
- Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.
Billionaire Hedge Funds
